Findings from Medical Center Blvd Broaden Understanding of Endometrial Stromal Tumors (Immunohistochemical Expression of Lymphoid Enhancer-binding Factor 1 In Low-grade Endometrial Stromal Tumors).

A recent study conducted at the Medical Center Blvd in Winston-Salem, North Carolina, has provided new insights into endometrial stromal tumors (ESTs). The study found that nuclear expression of beta-catenin, a marker of the Wnt/beta-catenin signaling pathway, was present in 50% to 92% of low-grade ESTs. The researchers also discovered that the lymphoid enhancer-binding factor 1 (LEF1) protein could be a useful marker in diagnosing low-grade ESTs and differentiating them from smooth muscle tumors. These findings may contribute to improved diagnosis and treatment of ESTs. [Extracted from the article]

Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)